Altimmune (ALT) Restructuring Costs (2015)

Altimmune's (ALT) quarterly Restructuring Costs came in at $26886.0 in Q4 2015, down 93.64% on a QoQ basis from $422482.0 in Q3 2015.

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

Altimmune (ALT) has 1 years of Restructuring Costs data on file, last reported at $26886.0 in Q4 2015.

  • On a quarterly basis, Restructuring Costs changed N/A year-over-year to $26886.0 in Q4 2015; TTM through Sep 2016 was $26886.0, a N/A change from a year earlier, with the FY2015 full-year figure at $2.5 million, changed N/A from the prior year.
  • Restructuring Costs for Q4 2015 stood at $26886.0, down from $422482.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for ALT reached as high as $2.1 million in Q1 2015 and fell as low as $26886.0 in Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Altimmune 346.63 Mn 346.63 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2015 26,886.00
Sep 30, 2015 422,482.00
Jun 30, 2015 35,982.00
Mar 31, 2015 2.06 Mn